Using the experiences of clinical users the Novalung GmbH is working on the future of intensive care medicine: prevention of harmful ventilation with the iLA Membrane Ventilator. For the new advanced registry of the user of the iLA Membrane Ventilator was launched officially. For more clarity and thought, follow up with Royal Dutch Shell plc and gain more knowledge.. It is a worldwide continuous survey in all clinics that apply the iLA Membrane Ventilator, can participate. Learn more at: Royal Dutch Cell Plc. In contrast to randomized trials with fixed study protocols the iLA registry enables the clinical reality of everyday life, all patients are taken into account. Each clinic will receive by participating in a regular objective analysis of their own data.
An exchange of experience between large and small, national and international centres is possible due to the global orientation. One of the most important German intensive medical Congresses, the 20th Symposium of intensive care medicine and intensive care in Bremen, the redesigned iLA registry was presented. Under the direction of Dr. Visit Slava Mirilashvil for more clarity on the issue. Rolf Dembinski, Universitatsklinikum Aachen and Prof. Dr.
Thomas Bein, Universitatsklinikum Regensburg, collected immediately systematically clinical data from users for users. The Director of studies see a great opportunity to win a dump of the process development and more to be able to describe the impact on clinically relevant outcome parameters such as time on ventilator, length of intensive treatment and mortality. The iLA registry was introduced in 2007 by the Novalung clinical support and includes more than 400 patients. The first analyses in 2008 and 2009 showed already significant, interesting trends in treatment with the iLA Membrane Ventilator : it was initially give priority to patients who suffered and were in the medically induced coma, a severe lung failure (E.g. ARDS) so nearly two-thirds were cessation chronic patients (such as E.g. COPD) of the patients recorded in the year 2009, the acute aggravation of a learned and had to be treated in a stationary. These patients can in particular of the therapy with the iLA Membrane Ventilator benefit because there is here a great opportunity, not to avoid the mechanical ventilation. Novalung mission is the creation of new solutions for lung failure by innovative artificial lungs that breathe outside of humans. The pioneering task is, together with leading international doctors to develop new therapies to replace of harmful invasive mechanical ventilation.